Papers
5
Total Citations
167
H-Index
4
About
Xiaobin Shang is a leading surgical oncologist specializing in esophageal squamous cell carcinoma (ESCC), with a focus on advancing minimally invasive and neoadjuvant treatment strategies. His research centers on optimizing surgical techniques—particularly robot-assisted McKeown esophagectomy—and integrating immunotherapy with chemotherapy to improve outcomes for locally advanced disease. Shang’s major contributions include demonstrating the superiority of robot-assisted over video-assisted thoracoscopic lymph node dissection around the left recurrent laryngeal nerve, a technically challenging procedure that reduces vocal cord palsy and pulmonary complications. His landmark REVATE trial (56 citations) and related work (38 citations) have helped define best practices in robotic esophagectomy. He also leads the Keystone-001 phase-II trial (62 citations), investigating pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy for stage III ESCC. With over 100 citations across his most-cited papers, Shang has also characterized the learning curve for robotic lymph node dissection in a cohort of 417 patients, providing critical guidance for surgical training. His work bridges surgical innovation and multimodal therapy, directly impacting clinical guidelines and patient survival in high-volume centers.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5